

Nicola Biagio Mercuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/813742/publications.pdf>

Version: 2024-02-01

477
papers

18,455
citations

16451

64
h-index

26613

107
g-index

484
all docs

484
docs citations

484
times ranked

16857
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in spasticity following functional electrical stimulation cycling in patients with spinal cord injury: A systematic review. <i>Journal of Spinal Cord Medicine</i> , 2022, 45, 10-23.	1.4	22
2	Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. <i>Neurological Sciences</i> , 2022, 43, 387-392.	1.9	6
3	Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey. <i>Neurological Sciences</i> , 2022, 43, 1197-1205.	1.9	10
4	Potent T cell-mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	9
5	Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?. <i>Neurological Sciences</i> , 2022, 43, 1993-2001.	1.9	7
6	Depressive symptoms in patients with epilepsy and clinically associated features in a single tertiary center. <i>Neurological Sciences</i> , 2022, 43, 1965-1974.	1.9	7
7	Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment. <i>Movement Disorders</i> , 2022, 37, 228-230.	3.9	7
8	Subjective sleep disorders and daytime sleepiness in patients with restrictive type anorexia nervosa and effects on quality of life: a case-control study. <i>Sleep and Biological Rhythms</i> , 2022, 20, 181-189.	1.0	1
9	Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 537-544.	2.8	3
10	Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1228.	2.4	11
11	Tau and Amyloid- β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters. <i>Frontiers in Neurology</i> , 2022, 13, 748599.	2.4	8
12	Effects of Ultramicrosized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study. <i>Pharmaceuticals</i> , 2022, 15, 253.	3.8	13
13	Brain Functional Connectivity in de novo Parkinson's Disease Patients Based on Clinical EEG. <i>Frontiers in Neurology</i> , 2022, 13, 844745.	2.4	13
14	Neurotrophins as Therapeutic Agents for Parkinson's Disease; New Chances From Focused Ultrasound?. <i>Frontiers in Neuroscience</i> , 2022, 16, 846681.	2.8	10
15	Early Life Social Stress Causes Sex- and Region-Dependent Dopaminergic Changes that Are Prevented by Minocycline. <i>Molecular Neurobiology</i> , 2022, , 1.	4.0	8
16	Pathophysiological Features of Nigral Dopaminergic Neurons in Animal Models of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4508.	4.1	16
17	Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence. <i>Neurological Sciences</i> , 2022, 43, 5355-5362.	1.9	6
18	Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 127-139.	2.6	8

#	ARTICLE	IF	CITATIONS
19	Using a Video Device and a Deep Learning-Based Pose Estimator to Assess Gait Impairment in Neurodegenerative Related Disorders: A Pilot Study. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4642.	2.5	7
20	¹⁸ F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment. <i>Journal of Neurology</i> , 2022, 269, 5356-5367.	3.6	13
21	Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson's Disease. <i>Brain Sciences</i> , 2022, 12, 739.	2.3	6
22	Lipidomics of Bioactive Lipids in Alzheimer's and Parkinson's Diseases: Where Are We?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6235.	4.1	19
23	Cognitive functioning, cerebrospinal fluid Alzheimer's disease biomarkers and cerebral glucose metabolism in late-onset epilepsy of unknown aetiology: A prospective study. <i>European Journal of Neuroscience</i> , 2022, 56, 5384-5396.	2.6	9
24	Perampanel Increases Cortical EEG Fast Activity in Child and Adult Patients Affected by Epilepsy: A Quantitative EEG Study. <i>Clinical EEG and Neuroscience</i> , 2021, 52, 360-370.	1.7	11
25	Sleep-wake cycle dysregulation in idiopathic REM sleep behaviour disorder. <i>Journal of Sleep Research</i> , 2021, 30, e13234.	3.2	7
26	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. <i>Journal of Affective Disorders</i> , 2021, 278, 339-340.	4.1	11
27	Sleep-disordered breathing and the risk of Alzheimer's disease. <i>Sleep Medicine Reviews</i> , 2021, 55, 101375.	8.5	79
28	How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 87-92.	2.2	1
29	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 51.	2.5	9
30	Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1031-1033.	3.9	15
31	Emerging Roles of Protease-Activated Receptors (PARs) in the Modulation of Synaptic Transmission and Plasticity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 869.	4.1	7
32	Obstructive sleep apnea syndrome and Alzheimer's disease pathology: may continuous positive airway pressure treatment delay cognitive deterioration?. <i>Sleep and Breathing</i> , 2021, 25, 2135-2139.	1.7	14
33	Investigating Different Forms of Hydrogen Sulfide in Cerebrospinal Fluid of Various Neurological Disorders. <i>Metabolites</i> , 2021, 11, 152.	2.9	8
34	A2A Receptor Dysregulation in Dystonia DYT1 Knock-Out Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2691.	4.1	7
35	Physical Exercise and Alzheimer's Disease: Effects on Pathophysiological Molecular Pathways of the Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2897.	4.1	30
36	Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111434.	4.6	11

#	ARTICLE	IF	CITATIONS
37	Perampanel effects on cognition and quantitative EEG in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 117, 107803.	1.7	2
38	Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. <i>Pharmaceuticals</i> , 2021, 14, 336.	3.8	21
39	Sleep problems affect quality of life in Parkinson's disease along disease progression. <i>Sleep Medicine</i> , 2021, 81, 307-311.	1.6	18
40	Design of an Innovative Methodology for Cerebrospinal Fluid Analysis: Preliminary Results. <i>Sensors</i> , 2021, 21, 3767.	3.8	4
41	Resilience to anhedonia-passive coping induced by early life experience is linked to a long-lasting reduction of Ih current in VTA dopaminergic neurons. <i>Neurobiology of Stress</i> , 2021, 14, 100324.	4.0	9
42	The Importance of Diagnosing and the Clinical Potential of Treating Obstructive Sleep Apnea to Delay Mild Cognitive Impairment and Alzheimer's Disease: A Special Focus on Cognitive Performance. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 515-533.	2.2	15
43	Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations. <i>Frontiers in Neurology</i> , 2021, 12, 678373.	2.4	14
44	Dopamine-dependent early synaptic and motor dysfunctions induced by α -synuclein in the nigrostriatal circuit. <i>Brain</i> , 2021, 144, 3477-3491.	7.6	49
45	Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease. <i>Progress in Neurobiology</i> , 2021, 202, 102031.	5.7	46
46	Effects of head trauma and sport participation in young-onset Parkinson's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 1185-1193.	2.8	11
47	Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up. <i>Epilepsy and Behavior</i> , 2021, 121, 108069.	1.7	18
48	Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer's Disease: Implications for Treatment. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 985-1000.	2.6	16
49	Sudomotor and cardiovascular autonomic function in de novo Parkinson's disease assessed by sudoscan and cardiovascular reflexes. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117502.	0.6	8
50	Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype. <i>European Journal of Neurology</i> , 2021, 28, 3965-3971.	3.3	7
51	Fampridine improves acute optic neuritis contributing to a long-lasting recovery of nerve function. <i>Neurological Sciences</i> , 2021, 42, 4833-4836.	1.9	2
52	Biofluids profile of α -Klotho in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 62-64.	2.2	8
53	Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias. <i>Neurobiology of Aging</i> , 2021, 105, 333-339.	3.1	14
54	Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. <i>Ageing Research Reviews</i> , 2021, 72, 101479.	10.9	48

#	ARTICLE	IF	CITATIONS
55	Movement disorders in primary central nervous system lymphoma: two unreported cases and a review of literature. <i>Neurological Sciences</i> , 2021, 42, 905-910.	1.9	2
56	Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4693.	2.4	2
57	CSF level of anti-aging protein β -klotho is inversely associated with β -synuclein in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119536.	0.6	0
58	Clinical and radiological phenotype of multiple sclerosis associated to coeliac disease: Monocentric experience. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118140.	0.6	0
59	Gut microbiota dysbiosis in Parkinson's disease patients: Early feature and biomarker of disease progression?. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119515.	0.6	0
60	Cognitive decline in late-onset epilepsy of undefined etiology: A longitudinal cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117709.	0.6	0
61	A2A receptors in mouse model of DYT1 primary dystonia. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117838.	0.6	0
62	Movement disorders related to primary central nervous system lymphoma: Two novel cases and a literature review. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119473.	0.6	0
63	Adult onset sporadic chorea: A single-centre retrospective study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119486.	0.6	0
64	“Creutzfeldt-Jacob disease or other rapidly progressive dementia? Diagnostic and prognostic value of EEG, brain MRI and CSF features” <i>Journal of the Neurological Sciences</i> , 2021, 429, 119000.	0.6	0
65	The Retinal Posterior Pole in Early Parkinson’s Disease: A Fundus Perimetry and SD-OCT Study. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 4005-4014.	1.8	3
66	The actigraphic documentation of circadian sleep-wake rhythm dysregulation in myotonic dystrophy type 1. <i>Sleep Medicine</i> , 2021, 88, 134-139.	1.6	5
67	What substance P might tell us about the prognosis and mechanism of Parkinson's disease?. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 131, 899-911.	6.1	5
68	Distortion Product Otoacoustic Emissions and Their Suppression as Predictors of Peripheral Auditory Damage in Migraine: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5007.	2.4	5
69	Perampanel may represent an effective treatment for the prevention of migraine comorbid with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 125, 108391.	1.7	5
70	More than sleep and wake disturbances: an actigraphic study showing the sleep-wake pattern dysregulation in epilepsy.. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 94, 95-99.	2.0	7
71	Long-Term Depression of Striatal DA Release Induced by mGluRs via Sustained Hyperactivity of Local Cholinergic Interneurons. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 798464.	3.7	1
72	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. <i>Current Neuropharmacology</i> , 2021, 19, .	2.9	1

#	ARTICLE	IF	CITATIONS
73	Assessment of Motor Impairments in Early Untreated Parkinson's Disease Patients: The Wearable Electronics Impact. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 120-130.	6.3	45
74	Seasonality of restless legs syndrome: symptom variability in winter and summer times. <i>Sleep Medicine</i> , 2020, 66, 10-14.	1.6	4
75	Technology-Based Objective Measures Detect Subclinical Axial Signs in Untreated, de novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 113-122.	2.8	25
76	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 180-184.	3.9	66
77	On the Modulatory Roles of Neuregulins/ErbB Signaling on Synaptic Plasticity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 275.	4.1	36
78	Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 5.	6.2	39
79	Protease-activated receptor 1 (PAR1) inhibits synaptic NMDARs in mouse nigral dopaminergic neurons. <i>Pharmacological Research</i> , 2020, 160, 105185.	7.1	5
80	Clinical course of paroxysmal dyskinesias throughout pregnancy. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 19-20.	2.2	5
81	Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102359.	2.0	13
82	Physical Activity Changes and Correlate Effects in Patients with Parkinson's Disease during COVID-19 Lockdown. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 797-802.	1.5	53
83	Heart Rate Variability Parameters During Psychogenic Non-epileptic Seizures: Comparison Between Patients With Pure PNES and Comorbid Epilepsy. <i>Frontiers in Neurology</i> , 2020, 11, 713.	2.4	13
84	Laterality of Auditory Dysfunction in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1283-1284.	3.9	4
85	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. <i>Neurological Sciences</i> , 2020, 41, 2671-2674.	1.9	6
86	Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study. <i>Epileptic Disorders</i> , 2020, 22, 309-316.	1.3	15
87	Autonomic symptoms, cardiovascular and sudomotor evaluation in de novo type 1 narcolepsy. <i>Clinical Autonomic Research</i> , 2020, 30, 557-562.	2.5	9
88	Autonomic functions in focal epilepsy: A comparison between lacosamide and carbamazepine monotherapy. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117095.	0.6	5
89	Insights on the Functional Interaction between Group 1 Metabotropic Glutamate Receptors (mGluRI) and ErbB Receptors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7913.	4.1	9
90	Sleep-Wake Cycle in Alzheimer's Disease Is Associated with Tau Pathology and Orexin Dysregulation. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 501-508.	2.6	47

#	ARTICLE	IF	CITATIONS
91	Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. <i>Neurological Sciences</i> , 2020, 41, 1373-1375.	1.9	59
92	Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. <i>Haematologica</i> , 2020, 105, 2056-2070.	3.5	70
93	Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 126.	3.4	5
94	Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnesic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 681-689.	2.6	27
95	Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. <i>Neurobiology of Aging</i> , 2020, 90, 119-124.	3.1	41
96	Amyloid- β 42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1171-1178.	2.6	11
97	Optogenetic Activation of Striatopallidal Neurons Reveals Altered HCN Gating in DYT1 Dystonia. <i>Cell Reports</i> , 2020, 31, 107644.	6.4	16
98	Transient upregulation of translational efficiency in prodromal and early symptomatic Tg2576 mice contributes to A β pathology. <i>Neurobiology of Disease</i> , 2020, 139, 104787.	4.4	8
99	Cerebellar White Matter Disruption in Alzheimer's Disease Patients: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 615-624.	2.6	21
100	Pitolisant for treating narcolepsy comorbid with Parkinson's disease. <i>Sleep Medicine</i> , 2020, 69, 86-87.	1.6	4
101	Dystonia: Sparse Synapses for D2 Receptors in Striatum of a DYT1 Knock-out Mouse Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1073.	4.1	5
102	Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 57-63.	2.2	16
103	Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 57-59.	2.2	0
104	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 11-16.	4.1	159
105	CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 19, 142-147.	1.4	4
106	Modified age-dependent expression of Nav1.6 in an ALS model correlates with motor cortex excitability alterations. <i>Neurobiology of Disease</i> , 2019, 130, 104532.	4.4	15
107	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019, 40, 2587-2594.	1.9	5
108	Hippocampal epileptogenesis in autoimmune encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2261-2269.	3.7	20

#	ARTICLE	IF	CITATIONS
109	The striatal-enriched protein Rhes is a critical modulator of cocaine-induced molecular and behavioral responses. <i>Scientific Reports</i> , 2019, 9, 15294.	3.3	16
110	Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis. <i>CNS Drugs</i> , 2019, 33, 1133-1139.	5.9	7
111	Feasibility of automated detection of sleep apnea using implantable pacemakers and defibrillators: a comparison with simultaneous polysomnography recording. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 56, 327-333.	1.3	11
112	Attention Allocation to Financial Information: The Role of Color and Impulsivity Personality Trait. <i>Frontiers in Neuroscience</i> , 2019, 13, 818.	2.8	4
113	Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay. <i>Frontiers in Neuroscience</i> , 2019, 13, 889.	2.8	25
114	Rhythmic auditory stimulation in gait rehabilitation for traumatic brain and spinal cord injury. <i>Journal of Clinical Neuroscience</i> , 2019, 69, 287-288.	1.5	16
115	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. <i>Nature Communications</i> , 2019, 10, 3945.	12.8	127
116	Task-oriented Motor Learning in Upper Extremity Rehabilitation Post Stroke. <i>Journal of Stroke Medicine</i> , 2019, 2, 95-104.	0.3	11
117	Treating TB human neuroectodermal cell line with retinoic acid induces the appearance of neuron-like voltage-gated ionic currents. <i>Brain Research</i> , 2019, 1711, 97-105.	2.2	0
118	Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 632-637.	3.9	9
119	Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL). <i>Tj ETQq1 1 0.784314 rgBT₅ /Overlook</i>	1.9	19
120	Subclinical cochlear dysfunction in newly diagnosed relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 55-60.	2.0	13
121	Neurotensin receptors inhibit mGluR I responses in nigral dopaminergic neurons via a process that undergoes functional desensitization by G-protein coupled receptor kinases. <i>Neuropharmacology</i> , 2019, 155, 76-88.	4.1	5
122	Dysbiosis of gut microbiota in a selected population of Parkinson's patients. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 124-130.	2.2	144
123	The effect of postural deformities on back function and pain in patients with Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 44, 419-424.	1.3	12
124	Impact of Pharmacological Inhibition of Hydrogen Sulphide Production in the SOD1G93A-ALS Mouse Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2550.	4.1	16
125	Cognitive rehabilitation post traumatic brain injury: A systematic review for emerging use of virtual reality technology. <i>Journal of Clinical Neuroscience</i> , 2019, 66, 209-219.	1.5	60
126	Effect of segmental muscle vibration on upper extremity functional ability poststroke. <i>Medicine (United States)</i> , 2019, 98, e14444.	1.0	27

#	ARTICLE	IF	CITATIONS
127	Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study. <i>Neurological Sciences</i> , 2019, 40, 1377-1382.	1.9	27
128	Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. <i>Epilepsy and Behavior</i> , 2019, 94, 178-182.	1.7	14
129	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and β -synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 97-105.	2.2	22
130	RGS2 rescues dopamine D2 receptor levels and signaling in <i>DYT1</i> dystonia mouse models. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	44
131	Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. <i>Frontiers in Neurology</i> , 2019, 10, 148.	2.4	89
132	Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity. <i>Journal of Neurology</i> , 2019, 266, 982-989.	3.6	14
133	Association between physical activity and dementia's risk factors in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 319-325.	2.8	26
134	The influence of postural deformities on neck function and pain in patients with Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 44, 79-84.	1.3	10
135	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. <i>Epilepsy and Behavior</i> , 2019, 101, 106592.	1.7	21
136	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. <i>Neurobiology of Aging</i> , 2019, 73, 61-67.	3.1	75
137	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 636-641.	3.6	28
138	Electrophysiological Characterization of Novel Effects of the Uptake-2 Blocker Decynium-22 (D-22) on Dopaminergic Neurons in the Substantia Nigra Pars Compacta. <i>Neuroscience</i> , 2019, 396, 154-165.	2.3	5
139	Postural and vestibular changes related to CPAP treatment in moderate-to-severe OSA patients: a 12-month longitudinal study. <i>Sleep and Breathing</i> , 2019, 23, 665-672.	1.7	13
140	New revolution in the assessment of cerebrospinal fluid orexinA: Enzyme-linked immunosorbent assay!. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 194-195.	1.8	4
141	Obstructive sleep apnea may induce orexinergic system and cerebral β -amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?. <i>Sleep Medicine</i> , 2019, 56, 171-176.	1.6	53
142	L-DOPA-quinone Mediated Recovery from GIRK Channel Firing Inhibition in Dopaminergic Neurons. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 431-436.	2.8	9
143	CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 3.	4.2	13
144	LTP-like cortical plasticity is associated with verbal memory impairment in Alzheimer's disease patients. <i>Brain Stimulation</i> , 2019, 12, 148-151.	1.6	46

#	ARTICLE	IF	CITATIONS
145	CSF α -synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 203-206.	2.2	30
146	Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 240-244.	2.4	21
147	Cerebral blood volume lesion extent predicts functional outcome in patients with vertebral and basilar artery occlusion. <i>International Journal of Stroke</i> , 2019, 14, 540-547.	5.9	25
148	Does continuous positive airway pressure treatment affect autonomic nervous system in patients with severe obstructive sleep apnea?. <i>Sleep Medicine</i> , 2018, 42, 68-72.	1.6	9
149	3,4-Methylenedioxymethamphetamine (MDMA) Alters Synaptic Dopamine Release in the Dorsal Striatum Through Nicotinic Receptors and DAT Inhibition. <i>Neuroscience</i> , 2018, 377, 69-76.	2.3	9
150	Ambra1 Shapes Hippocampal Inhibition/Excitation Balance: Role in Neurodevelopmental Disorders. <i>Molecular Neurobiology</i> , 2018, 55, 7921-7940.	4.0	28
151	The role of dopaminergic midbrain in Alzheimer's disease: Translating basic science into clinical practice. <i>Pharmacological Research</i> , 2018, 130, 414-419.	7.1	64
152	Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study. <i>Epilepsy and Behavior</i> , 2018, 80, 173-176.	1.7	40
153	Neuregulin 1/ErbB signalling modulates hippocampal mGluR1-dependent LTD and object recognition memory. <i>Pharmacological Research</i> , 2018, 130, 12-24.	7.1	21
154	Lacosamide in the Management of Behavioral Symptoms in Frontotemporal Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 364-365.	1.3	4
155	Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. <i>Sleep Medicine</i> , 2018, 41, 113-114.	1.6	16
156	Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine. <i>Epilepsy & Behavior Case Reports</i> , 2018, 10, 35-37.	1.5	16
157	Does Pisa syndrome affect upper limb function in patients with Parkinson's disease? An observational cross-sectional study. <i>NeuroRehabilitation</i> , 2018, 42, 143-148.	1.3	10
158	miR-34b/c Regulates Wnt1 and Enhances Mesencephalic Dopaminergic Neuron Differentiation. <i>Stem Cell Reports</i> , 2018, 10, 1237-1250.	4.8	47
159	Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study. <i>Radiologia Medica</i> , 2018, 123, 202-208.	7.7	5
160	Enhanced mu opioid receptor-dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. <i>Movement Disorders</i> , 2018, 33, 310-320.	3.9	20
161	mGluR1-Dependent Long Term Depression in Rodent Midbrain Dopamine Neurons Is Regulated by Neuregulin 1/ErbB Signaling. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 346.	2.9	15
162	Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimer's Disease Patients Showing Neuropsychiatric Symptoms. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 993-999.	2.6	22

#	ARTICLE	IF	CITATIONS
163	Pisa Syndrome in Parkinson's Disease: Evidence for Bilateral Vestibulospinal Dysfunction. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	1.1	6
164	Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: a preliminary study. <i>Sleep Medicine</i> , 2018, 52, 163-167.	1.6	19
165	Tissue degeneration in ALS affected spinal cord evaluated by Raman spectroscopy. <i>Scientific Reports</i> , 2018, 8, 13110.	3.3	9
166	Effectiveness of robot-assisted gait training on motor impairments in people with Parkinson's disease: a systematic review and meta-analysis. <i>International Journal of Rehabilitation Research</i> , 2018, 41, 287-296.	1.3	34
167	Dopamine loss alters the hippocampus-nucleus accumbens synaptic transmission in the Tg2576 mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2018, 116, 142-154.	4.4	50
168	Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum. <i>ELife</i> , 2018, 7, .	6.0	60
169	Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 80-81.	2.2	25
170	Reversal of dopamine-mediated firing inhibition through activation of the dopamine transporter in substantia nigra pars compacta neurons. <i>British Journal of Pharmacology</i> , 2018, 175, 3534-3547.	5.4	13
171	When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 38.	3.4	25
172	Centrality of Early Synaptopathy in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 103.	2.4	41
173	Proteomics and Toxicity Analysis of Spinal-Cord Primary Cultures upon Hydrogen Sulfide Treatment. <i>Antioxidants</i> , 2018, 7, 87.	5.1	16
174	Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 525-532.	2.6	59
175	Transcranial magnetic stimulation predicts cognitive decline in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1237-1242.	1.9	64
176	Dystonia as a network disorder: a concept in evolution. <i>Current Opinion in Neurology</i> , 2018, 31, 498-503.	3.6	57
177	Comments on: "Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review". <i>Sleep Medicine Reviews</i> , 2018, 40, 215-216.	8.5	1
178	In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 72, 72-82.	3.1	58
179	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	2.8	25
180	From Traumatic Childhood to Cocaine Abuse: The Critical Function of the Immune System. <i>Biological Psychiatry</i> , 2018, 84, 905-916.	1.3	56

#	ARTICLE	IF	CITATIONS
181	Continuous Positive Airway Pressure Treatment May Improve Optic Nerve Function in Obstructive Sleep Apnea: An Electrophysiological Study. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 953-958.	2.6	12
182	Physical activity contradictorily affects bone mineral density in obstructive sleep apnea patients at different ages. <i>Sleep Medicine</i> , 2017, 32, 273.	1.6	0
183	Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsies: further data. <i>Epilepsy and Behavior</i> , 2017, 67, 137-138.	1.7	13
184	Acid-sensing ion channel 1a is required for mGlu receptor dependent long-term depression in the hippocampus. <i>Pharmacological Research</i> , 2017, 119, 12-19.	7.1	18
185	The role of adiponectin receptors in the regulation of synaptic transmission in the hippocampus. <i>Synapse</i> , 2017, 71, e21964.	1.2	19
186	Obstructive sleep apnoea as a risk factor for osteopenia and osteoporosis in the male population: further data and comments. <i>European Respiratory Journal</i> , 2017, 49, 1602471.	6.7	1
187	Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer's Disease Biomarkers Changes. <i>Sleep</i> , 2017, 40, .	1.1	113
188	Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. <i>Nature Communications</i> , 2017, 8, 14727.	12.8	308
189	Intermittent Short Sleep May Contribute to Orexinergic Signaling Dysregulation in Alzheimer's Disease. <i>Sleep</i> , 2017, 40, .	1.1	1
190	Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings. <i>Clinical Neurology and Neurosurgery</i> , 2017, 156, 63-65.	1.4	10
191	Facial diplegia resembling bilateral Ramsay Hunt Syndrome. <i>Journal of the Neurological Sciences</i> , 2017, 376, 109-111.	0.6	5
192	TRPV1 polymorphisms and risk of interferon β -induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 305, 172-174.	2.3	5
193	Letter re: Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. <i>Neurology</i> , 2017, 89, 1532-1532.	1.1	0
194	Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. <i>Journal of Neurology</i> , 2017, 264, 2215-2223.	3.6	39
195	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1621-1625.	2.8	27
196	Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1531-1540.	2.0	54
197	Functional alterations of the dopaminergic and glutamatergic systems in spontaneous β -synuclein overexpressing rats. <i>Experimental Neurology</i> , 2017, 287, 21-33.	4.1	34
198	Vitamin D status of male OSAS patients improved after long-term CPAP treatment mainly in obese subjects. <i>Sleep Medicine</i> , 2017, 29, 81-85.	1.6	30

#	ARTICLE	IF	CITATIONS
199	On the properties of identified dopaminergic neurons in the mouse substantia nigra and ventral tegmental area. <i>European Journal of Neuroscience</i> , 2017, 45, 92-105.	2.6	46
200	Sleep apnoeas may represent a reversible risk factor for amyloid- β^2 pathology. <i>Brain</i> , 2017, 140, e75-e75.	7.6	23
201	Current Concepts on the Physiopathological Relevance of Dopaminergic Receptors. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 27.	3.7	50
202	Commentary: Sleep Changes without Medial Temporal Lobe or Brain Cortical Changes in Community-Dwelling Individuals with Subjective Cognitive Decline. <i>Frontiers in Neurology</i> , 2017, 8, 262.	2.4	2
203	Dopamine: Cellular Actions $\hat{+}$. , 2017, , .		0
204	Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression. , 2017, 07, .		4
205	Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 339-345.	1.4	12
206	Heart rate variability in untreated newly diagnosed temporal lobe epilepsy: Evidence for ictal sympathetic dysregulation. <i>Epilepsia</i> , 2016, 57, 418-426.	5.1	45
207	Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2040-2049.	6.4	73
208	Epilepsy, amyloid- β^2 , and D1 dopamine receptors: a possible pathogenetic link?. <i>Neurobiology of Aging</i> , 2016, 48, 161-171.	3.1	71
209	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 77-94.	3.2	163
210	Interaction between interleukin- $1\beta^2$ and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2016, 13, 231.	7.2	35
211	Optic Nerve Dysfunction in Obstructive Sleep Apnea: An Electrophysiological Study. <i>Sleep</i> , 2016, 39, 19-23.	1.1	26
212	Obstructive sleep apnoea and bone health. <i>European Respiratory Journal</i> , 2016, 48, 1249-1250.	6.7	2
213	Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1-deficient mice. <i>Synapse</i> , 2016, 70, 223-230.	1.2	14
214	Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. <i>Sleep and Breathing</i> , 2016, 20, 277-283.	1.7	19
215	Astrocyte-Dependent Vulnerability to Excitotoxicity in Spermine Oxidase-Overexpressing Mouse. <i>NeuroMolecular Medicine</i> , 2016, 18, 50-68.	3.4	32
216	Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 40, 120-126.	3.1	96

#	ARTICLE	IF	CITATIONS
217	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. <i>Sleep Medicine</i> , 2016, 21, 140-144.	1.6	55
218	Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice. <i>Neurobiology of Disease</i> , 2016, 91, 21-36.	4.4	36
219	Effective treatment of nocturnal frontal lobe epilepsy with lacosamide: a report of two cases. <i>Sleep Medicine</i> , 2016, 23, 121-122.	1.6	10
220	Persistent elevation of D-Aspartate enhances NMDA receptor-mediated responses in mouse substantia nigra pars compacta dopamine neurons. <i>Neuropharmacology</i> , 2016, 103, 69-78.	4.1	33
221	Obstructive sleep apnoea as a risk factor for osteopenia and osteoporosis in the male population. <i>European Respiratory Journal</i> , 2016, 47, 987-990.	6.7	26
222	Inhibition of hippocampal plasticity in rats performing contrafreeloading for water under repeated administrations of pramipexole. <i>Psychopharmacology</i> , 2016, 233, 727-737.	3.1	7
223	Development of Collateral Veins as a Favorable Prognostic Factor for Complete Recovery in Cerebral Venous Thrombosis Due to Tribulus Terrestris. <i>International Journal of Stroke</i> , 2015, 10, E66-E67.	5.9	6
224	Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1476-1478.	2.2	4
225	Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinson's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 261.	2.4	2
226	Estrogen Deficiency Hampers the Beneficial Effect of Continuous Positive Airway Pressure Therapy on Serum Vitamin D Concentrations in Postmenopausal Women Affected by Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 1473-1474.	2.6	12
227	Continuous Positive Airway Pressure Treatment Increases Serum Vitamin D Levels in Male Patients with Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 603-607.	2.6	47
228	Restless Legs Syndrome and Poliomyelitis: New Evidences of an Old Observation?. <i>Frontiers in Neurology</i> , 2015, 6, 23.	2.4	6
229	MicroRNA expression is dysregulated in narcolepsy: a new evidence?. <i>Sleep Medicine</i> , 2015, 16, 1027-1028.	1.6	3
230	Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system?. <i>Sleep Medicine</i> , 2015, 16, 1071-1076.	1.6	10
231	Dopaminergic dysfunction is associated with IL-1 β -dependent mood alterations in experimental autoimmune encephalomyelitis. <i>Neurobiology of Disease</i> , 2015, 74, 347-358.	4.4	42
232	Oral l-carnitine as treatment for narcolepsy without cataplexy during pregnancy: A case report. <i>Journal of the Neurological Sciences</i> , 2015, 348, 282-283.	0.6	9
233	Evidence of hydrogen sulfide involvement in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2015, 77, 697-709.	5.3	45
234	Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldt-Jakob disease. <i>Journal of the Neurological Sciences</i> , 2015, 348, 274-276.	0.6	9

#	ARTICLE	IF	CITATIONS
235	Restless legs syndrome and post polio syndrome: a case-control study. <i>European Journal of Neurology</i> , 2015, 22, 472-478.	3.3	15
236	Bilateral thalamic stroke due to nasal ephedrine and naphazoline use. <i>Neurological Sciences</i> , 2015, 36, 1285-1286.	1.9	4
237	Presynaptic c-Jun N-terminal Kinase 2 regulates NMDA receptor-dependent glutamate release. <i>Scientific Reports</i> , 2015, 5, 9035.	3.3	41
238	Refractory restless legs syndrome remitting after dual kidney transplantation. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 81-83.	2.2	2
239	Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons. <i>Molecular Psychiatry</i> , 2015, 20, 959-973.	7.9	36
240	Cocaine Dependence and Stroke: Pathogenesis and Management. <i>Current Neurovascular Research</i> , 2015, 12, 163-172.	1.1	37
241	The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option. <i>Current Neuropharmacology</i> , 2015, 13, 815-818.	2.9	13
242	Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart. <i>PLoS ONE</i> , 2014, 9, e101763.	2.5	26
243	Stimulation of μ Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism. <i>Journal of Neuroscience</i> , 2014, 34, 12953-12962.	3.6	11
244	Dysfunctional dopaminergic neurotransmission in asocial BTBR mice. <i>Translational Psychiatry</i> , 2014, 4, e427-e427.	4.8	59
245	Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals. <i>Translational Psychiatry</i> , 2014, 4, e417-e417.	4.8	47
246	CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?. <i>Journal of Sleep Research</i> , 2014, 23, 420-424.	3.2	37
247	Effects of epilepsy treatment on sleep architecture and daytime sleepiness: An evidence-based review of objective sleep metrics. <i>Epilepsia</i> , 2014, 55, 777-778.	5.1	3
248	Effects of Phenobarbital and Levetiracetam on PR and QTc Intervals in Patients with Post-Stroke Seizure. <i>Clinical Drug Investigation</i> , 2014, 34, 879-886.	2.2	15
249	Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires. <i>European Journal of Neurology</i> , 2014, 21, 929-934.	3.3	37
250	Familiar trajectories facilitate the interpretation of physical forces when intercepting a moving target. <i>Experimental Brain Research</i> , 2014, 232, 3803-3811.	1.5	9
251	Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. <i>Neurology</i> , 2014, 83, 572-573.	1.1	4
252	Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis. <i>Epilepsy & Behavior Case Reports</i> , 2014, 2, 161-163.	1.5	2

#	ARTICLE	IF	CITATIONS
253	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1498.	9.0	262
254	Interleukin-1 β Promotes Long-Term Potentiation in Patients with Multiple Sclerosis. <i>NeuroMolecular Medicine</i> , 2014, 16, 38-51.	3.4	64
255	May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy?. <i>Sleep Medicine</i> , 2014, 15, 1424.	1.6	7
256	Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates L-DOPA-induced dyskinesia in dopamine-denervated mice. <i>Experimental Neurology</i> , 2014, 261, 733-743.	4.1	29
257	Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. <i>Molecular and Cellular Neurosciences</i> , 2014, 62, 1-9.	2.2	23
258	Is autonomic nervous system involved in restless legs syndrome during wakefulness?. <i>Sleep Medicine</i> , 2014, 15, 1392-1397.	1.6	45
259	<i>PINK1</i> heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. <i>Movement Disorders</i> , 2014, 29, 41-53.	3.9	40
260	Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. <i>Journal of Neurology</i> , 2014, 261, 1832-1836.	3.6	25
261	Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study. <i>Journal of Neurology</i> , 2014, 261, 889-893.	3.6	21
262	Paradoxical Abatement of Striatal Dopaminergic Transmission by Cocaine and Methylphenidate. <i>Journal of Biological Chemistry</i> , 2014, 289, 264-274.	3.4	27
263	Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions. <i>Neuropharmacology</i> , 2014, 76, 127-136.	4.1	27
264	Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta. <i>Neuropharmacology</i> , 2014, 79, 467-475.	4.1	19
265	Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia. <i>Pharmacological Research</i> , 2014, 81, 83-90.	7.1	22
266	Multiple sleep latency test may be not sensitive in obstructive sleep apnea with comorbid narcolepsy revealed by low cerebrospinal fluid orexin levels. <i>Sleep Medicine</i> , 2014, 15, 1171.	1.6	2
267	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. <i>Biological Psychiatry</i> , 2014, 75, 701-710.	1.3	56
268	Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation. <i>Neuroscience</i> , 2013, 252, 118-124.	2.3	15
269	Calcineurin Inhibition Rescues Early Synaptic Plasticity Deficits in a Mouse Model of Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 541-548.	3.4	45
270	Dual effects of L-DOPA on nigral dopaminergic neurons. <i>Experimental Neurology</i> , 2013, 247, 582-594.	4.1	39

#	ARTICLE	IF	CITATIONS
271	Unilateral spatial neglect and alien limb phenomenon may be early features of Creutzfeldt-Jakob disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 379-381.	2.2	4
272	Effects of zonisamide as add-on therapy on sleep-wake cycle in focal epilepsy: A polysomnographic study. <i>Epilepsy and Behavior</i> , 2013, 26, 170-174.	1.7	29
273	Over-expression of N-type calcium channels in cortical neurons from a mouse model of Amyotrophic Lateral Sclerosis. <i>Experimental Neurology</i> , 2013, 247, 349-358.	4.1	45
274	Synaptic Plasticity and PDGF Signaling Defects Underlie Clinical Progression in Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2013, 33, 19112-19119.	3.6	70
275	Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1359.	4.3	28
276	Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e54666.	2.5	123
277	Electroencephalography and Dementia: A Literature Review and Future Perspectives. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 512-519.	1.4	6
278	Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease. <i>Functional Neurology</i> , 2013, 28, 101-5.	1.3	10
279	Spasticity as an ictal pattern due to excitotoxic upper motor neuron damage. <i>Epilepsy and Behavior</i> , 2012, 25, 397-400.	1.7	1
280	Targeting Synaptic Dysfunction in Alzheimer's Disease Therapy. <i>Molecular Neurobiology</i> , 2012, 46, 572-587.	4.0	80
281	Therapeutic potential of targeting hydrogen peroxide metabolism in the treatment of brain ischaemia. <i>British Journal of Pharmacology</i> , 2012, 166, 1211-1224.	5.4	58
282	Insulin Receptor β -Subunit Haploinsufficiency Impairs Hippocampal Late-Phase LTP and Recognition Memory. <i>NeuroMolecular Medicine</i> , 2012, 14, 262-269.	3.4	58
283	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. <i>PLoS ONE</i> , 2012, 7, e38312.	2.5	18
284	A continuous high frequency stimulation of the subthalamic nucleus determines a suppression of excitatory synaptic transmission in nigral dopaminergic neurons recorded in vitro. <i>Experimental Neurology</i> , 2012, 233, 292-302.	4.1	17
285	Hippocampus versus entorhinal cortex decoupling by an NR2 subunit-specific block of NMDA receptors in a rat in vitro model of temporal lobe epilepsy. <i>Epilepsia</i> , 2012, 53, e80-4.	5.1	15
286	Age-Related Changes of Hippocampal Synaptic Plasticity in β PP-Null Mice are Restored by NGF Through p75NTR. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 265-272.	2.6	11
287	Effect of Memantine on Resting State Default Mode Network Activity in Alzheimer's Disease. <i>Drugs and Aging</i> , 2011, 28, 205-217.	2.7	57
288	L-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?. <i>Progress in Neurobiology</i> , 2011, 94, 389-407.	5.7	100

#	ARTICLE	IF	CITATIONS
289	Persistent increase of d-aspartate in d-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. <i>Neurobiology of Aging</i> , 2011, 32, 2061-2074.	3.1	60
290	Increased d-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. <i>Neurobiology of Aging</i> , 2011, 32, 2229-2243.	3.1	70
291	Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons. <i>Frontiers in Systems Neuroscience</i> , 2011, 5, 56.	2.5	16
292	The Protective Role of Catalase against Cerebral Ischemia <i>in Vitro</i> and <i>in Vivo</i> . <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 735-747.	2.1	33
293	Properties of dopaminergic neurons in organotypic mesencephalic-striatal co-cultures - evidence for a facilitatory effect of dopamine on the glutamatergic input mediated by α -1 adrenergic receptors. <i>European Journal of Neuroscience</i> , 2011, 33, 1622-1636.	2.6	11
294	Loss of striatal cannabinoid CB1 receptor function in attention-deficit/hyperactivity disorder mice with point mutation of the dopamine transporter. <i>European Journal of Neuroscience</i> , 2011, 34, 1369-1377.	2.6	23
295	Behavioral, Neurochemical, and Electrophysiological Changes in an Early Spontaneous Mouse Model of Nigrostriatal Degeneration. <i>Neurotoxicity Research</i> , 2011, 20, 170-181.	2.7	12
296	Transient ischemic attack as initial manifestation of acute promyelocytic leukemia. <i>Leukemia Research</i> , 2011, 35, e134-e135.	0.8	1
297	N-Glycans mutations rule oligomeric assembly and functional expression of P2X3 receptor for extracellular ATP. <i>Glycobiology</i> , 2011, 21, 634-643.	2.5	15
298	Paraquat and Rotenone-Induced Models of Parkinson's Disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 313-322.	2.1	86
299	Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2010, 38, 434-445.	4.4	92
300	Identification of distinct cellular pools of interleukin-1 β during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat. <i>Brain Research</i> , 2010, 1313, 259-269.	2.2	32
301	<i>N</i> -ethyl lidocaine (QX-314) protects striatal neurons against ischemia: An <i>in vitro</i> electrophysiological study. <i>Synapse</i> , 2010, 64, 161-168.	1.2	3
302	Trace amines depress D ₂ autoreceptor-mediated responses on midbrain dopaminergic cells. <i>British Journal of Pharmacology</i> , 2010, 160, 1509-1520.	5.4	22
303	Firing properties and functional connectivity of substantia nigra pars compacta neurones recorded with a multi-electrode array <i>in vitro</i> . <i>Journal of Physiology</i> , 2010, 588, 1719-1735.	2.9	27
304	Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. <i>Learning and Memory</i> , 2010, 17, 236-240.	1.3	26
305	Role of Aberrant Striatal Dopamine D ₁ Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine. <i>Journal of Neuroscience</i> , 2010, 30, 11043-11056.	3.6	66
306	Metabotropic Glutamate Receptor 1 Mediates the Electrophysiological and Toxic Actions of the Cycad Derivative <i>N</i> -Methylamino-L-Alanine on Substantia Nigra Pars Compacta DAergic Neurons. <i>Journal of Neuroscience</i> , 2010, 30, 5176-5188.	3.6	58

#	ARTICLE	IF	CITATIONS
307	Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 83-90.	2.1	20
308	Chapter 17 (â€“)â€“Linalool Attenuates Allodynia in Neuropathic Pain Induced by Spinal Nerve Ligation in C57/Bl6 Mice. <i>International Review of Neurobiology</i> , 2009, 85, 221-235.	2.0	34
309	Chapter 25 Oxidative Stress in Stroke Pathophysiology. <i>International Review of Neurobiology</i> , 2009, 85, 363-374.	2.0	31
310	Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine. <i>Movement Disorders</i> , 2009, 24, 126-129.	3.9	78
311	Reelin haploinsufficiency reduces the density of PV+ neurons in circumscribed regions of the striatum and selectively alters striatal-based behaviors. <i>Psychopharmacology</i> , 2009, 204, 511-521.	3.1	34
312	Ethanol enhances GABA _B -mediated inhibitory postsynaptic transmission on rat midbrain dopaminergic neurons by facilitating GIRK currents. <i>European Journal of Neuroscience</i> , 2009, 29, 1369-1377.	2.6	39
313	Acute action of rotenone on nigral dopaminergic neurons â€“ involvement of reactive oxygen species and disruption of Ca ²⁺ homeostasis. <i>European Journal of Neuroscience</i> , 2009, 30, 1849-1859.	2.6	72
314	The anorexic agents, sibutramine and fenfluramine, depress GABA _B -induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells. <i>British Journal of Pharmacology</i> , 2009, 156, 962-969.	5.4	7
315	Rapid constitutive and ligand-activated endocytic trafficking of P2X ₃ receptor. <i>Journal of Neurochemistry</i> , 2009, 109, 1031-1041.	3.9	34
316	Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. <i>Experimental Neurology</i> , 2009, 215, 368-379.	4.1	127
317	Substantia Nigra Control of Basal Ganglia Nuclei. , 2009, , 91-101.		9
318	Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. <i>Synapse</i> , 2008, 62, 783-789.	1.2	14
319	Neuroprotective effect of hydrogen peroxide on an <i>in vitro</i> model of brain ischaemia. <i>British Journal of Pharmacology</i> , 2008, 153, 1022-1029.	5.4	34
320	Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. <i>Molecular and Cellular Neurosciences</i> , 2008, 37, 236-246.	2.2	79
321	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. <i>Medical Hypotheses</i> , 2008, 71, 162.	1.5	0
322	Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion. <i>Neuroscience</i> , 2008, 152, 8-17.	2.3	59
323	The midbrain slice preparation. An <i>in vitro</i> model to select potential anti-parkinsonian drugs?. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S150-S153.	2.2	1
324	Synaptic plasticity in the basal ganglia: A similar code for physiological and pathological conditions. <i>Progress in Neurobiology</i> , 2008, 84, 343-362.	5.7	25

#	ARTICLE	IF	CITATIONS
325	The l-amino acid carrier inhibitor 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH) reduces l-dopa-elicited responses in dopaminergic neurons of the substantia nigra pars compacta. <i>Experimental Neurology</i> , 2008, 212, 230-233.	4.1	15
326	Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. <i>Brain</i> , 2008, 132, 285-287.	7.6	50
327	Memantine Inhibits ATP-Dependent K ⁺ Conductances in Dopamine Neurons of the Rat Substantia Nigra Pars Compacta. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 721-729.	2.5	25
328	The Blockade of K ⁺ ATP Channels has Neuroprotective Effects in an In Vitro Model of Brain Ischemia. <i>International Review of Neurobiology</i> , 2007, 82, 383-395.	2.0	29
329	Selective disarrangement of the rostral telencephalic cholinergic system in heterozygous reeler mice. <i>Neuroscience</i> , 2007, 144, 834-844.	2.3	12
330	Altered calcium homeostasis in motor neurons following AMPA receptor but not voltage-dependent calcium channels TM activation in a genetic model of amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2007, 28, 90-100.	4.4	47
331	N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors. <i>Neuropsychopharmacology</i> , 2007, 32, 298-308.	5.4	141
332	Electrophysiologic Changes in Ventral Midbrain Dopaminergic Neurons Resulting from (+/Δ ^Δ) -3,4-Methylenedioxymethamphetamine (MDMA ^Δ Δ ^Δ Ecstasy ^Δ Δ ^Δ). <i>Biological Psychiatry</i> , 2007, 62, 680-686.	1.3	8
333	Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. <i>European Journal of Neuroscience</i> , 2007, 25, 1631-1640.	2.6	37
334	Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses. <i>Biological Psychiatry</i> , 2006, 60, 436-443.	1.3	43
335	Molecular and synaptic changes in the hippocampus underlying superior spatial abilities in pre-symptomatic G93A ^{+/+} mice overexpressing the human Cu/Zn superoxide dismutase (Gly93 ^Δ Δ ^Δ ALA) mutation. <i>Experimental Neurology</i> , 2006, 197, 505-514.	4.1	43
336	Altered cortico-striatal synaptic plasticity and related behavioural impairments in reeler mice. <i>European Journal of Neuroscience</i> , 2006, 24, 2061-2070.	2.6	54
337	On the Effects of Psychostimulants, Antidepressants, and the Antiparkinsonian Drug Levodopa on Dopamine Neurons. <i>Annals of the New York Academy of Sciences</i> , 2006, 1074, 320-329.	3.8	15
338	The P2Y ₄ receptor forms homo-oligomeric complexes in several CNS and PNS neuronal cells. <i>Purinergic Signalling</i> , 2006, 2, 575-582.	2.2	23
339	Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: Role of Na ⁺ /K ⁺ ATPase. <i>Neurobiology of Disease</i> , 2006, 23, 54-60.	4.4	51
340	Role of lifestyle factors on plasma homocysteine levels in Parkinson's disease patients treated with levodopa. <i>Nutritional Neuroscience</i> , 2006, 9, 11-16.	3.1	20
341	Temperature Sensitivity of Dopaminergic Neurons of the Substantia Nigra Pars Compacta: Involvement of Transient Receptor Potential Channels. <i>Journal of Neurophysiology</i> , 2005, 94, 3069-3080.	1.8	98
342	Protective role of hydrogen peroxide in oxygen-deprived dopaminergic neurones of the rat substantia nigra. <i>Journal of Physiology</i> , 2005, 568, 97-110.	2.9	23

#	ARTICLE	IF	CITATIONS
343	Trace amines reduce GABAB receptor-mediated presynaptic inhibition at GABAergic synapses of the rat substantia nigra pars compacta. <i>Brain Research</i> , 2005, 1062, 175-178.	2.2	14
344	Distinct Mechanisms of Presynaptic Inhibition at GABAergic Synapses of the Rat Substantia Nigra Pars Compacta. <i>Journal of Neurophysiology</i> , 2005, 94, 1992-2003.	1.8	25
345	Activation of TRPV1 in the VTA Excites Dopaminergic Neurons and Increases Chemical- and Noxious-Induced Dopamine Release in the Nucleus Accumbens. <i>Neuropsychopharmacology</i> , 2005, 30, 864-870.	5.4	120
346	Trace Amines Depress GABAB Response in Dopaminergic Neurons by Inhibiting G- $\beta\gamma$ -Gated Inwardly Rectifying Potassium Channels. <i>Molecular Pharmacology</i> , 2005, 67, 1283-1290.	2.3	31
347	Dopamine-containing Neurons are Silenced by Energy Deprivation: A Defensive Response or Beginning of Cell Death?. <i>NeuroToxicology</i> , 2005, 26, 857-868.	3.0	12
348	Acute Effects of 6-Hydroxydopamine on Dopaminergic Neurons of the Rat Substantia Nigra Pars Compacta In Vitro. <i>NeuroToxicology</i> , 2005, 26, 869-881.	3.0	34
349	The "magic" of -dopa: why is it the gold standard Parkinson's disease therapy?. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 341-344.	8.7	199
350	Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. <i>Biological Psychiatry</i> , 2005, 57, 361-365.	1.3	54
351	Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. <i>Pharmacological Research</i> , 2005, 52, 367-375.	7.1	37
352	Trace Amines Cause More than One Effect on Dopaminergic Neurons. , 2005, , 161-175.		0
353	Voltage-Gated Calcium Channels Mediate Intracellular Calcium Increase in Weaver Dopaminergic Neurons During Stimulation of D2 and GABAB Receptors. <i>Journal of Neurophysiology</i> , 2004, 92, 3368-3374.	1.8	17
354	Preserved Fronto-Striatal Plasticity and Enhanced Procedural Learning in a Transgenic Mouse Model of Alzheimer's Disease Overexpressing Mutant hAPP ^{swe} . <i>Learning and Memory</i> , 2004, 11, 447-452.	1.3	43
355	Blockade of Nociceptin/Orphanin FQ Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior. <i>Journal of Neuroscience</i> , 2004, 24, 6659-6666.	3.6	109
356	Presynaptic Modulation of Spontaneous Inhibitory Postsynaptic Currents by Gamma-hydroxybutyrate in the Substantia Nigra Pars Compacta. <i>Neuropsychopharmacology</i> , 2004, 29, 537-543.	5.4	21
357	A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic Transmission. <i>Neuropsychopharmacology</i> , 2004, 29, 1488-1497.	5.4	139
358	Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones. <i>British Journal of Pharmacology</i> , 2004, 141, 644-652.	5.4	33
359	Transient receptor potential-like channels mediate metabotropic glutamate receptor EPSCs in rat dopamine neurones. <i>Journal of Physiology</i> , 2004, 555, 323-330.	2.9	72
360	Gamma-hydroxybutyrate and ethanol depress spontaneous excitatory postsynaptic currents in dopaminergic neurons of the substantia nigra. <i>Brain Research</i> , 2004, 997, 62-66.	2.2	23

#	ARTICLE	IF	CITATIONS
361	Excessive and precocious glutamate release in a mouse model of amyotrophic lateral sclerosis. <i>Neuropharmacology</i> , 2004, 46, 782-792.	4.1	48
362	Inhibitory effects of trace amines on rat midbrain dopaminergic neurons. <i>Neuropharmacology</i> , 2004, 46, 807-814.	4.1	44
363	Cu/Zn-superoxide dismutase (GLY93 $\hat{+}$ ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture. <i>Neurobiology of Disease</i> , 2004, 15, 340-350.	4.4	67
364	Cellular localization of TRPC3 channel in rat brain: preferential distribution to oligodendrocytes. <i>Neuroscience Letters</i> , 2004, 365, 137-142.	2.1	34
365	Methamidophos transiently inhibits neuronal nicotinic receptors of rat substantia nigra dopaminergic neurons via open channel block. <i>Neuroscience Letters</i> , 2004, 369, 208-213.	2.1	5
366	Involvement of transient receptor potential-like channels in responses to mGluR-I activation in midbrain dopamine neurons. <i>European Journal of Neuroscience</i> , 2003, 18, 2133-2145.	2.6	123
367	D-Tubocurarine reduces GABA responses in rat substantia nigra dopamine neurons. <i>Synapse</i> , 2003, 47, 236-239.	1.2	5
368	Actions of the sodium channel inhibitor 202W92 on rat midbrain dopaminergic neurons. <i>Synapse</i> , 2003, 48, 123-130.	1.2	3
369	Depression of mGluR-mediated IPSCs by 5-HT in dopamine neurons of the rat substantia nigra pars compacta. <i>European Journal of Neuroscience</i> , 2003, 18, 2743-2750.	2.6	20
370	$\hat{+}$ -amino-3-hydroxy-5-methyl-isoxazole-4-propionate receptors in spinal cord motor neurons are altered in transgenic mice overexpressing human Cu,Zn superoxide dismutase (Gly93 $\hat{+}$ Ala) mutation. <i>Neuroscience</i> , 2003, 122, 47-58.	2.3	33
371	Altered long-term corticostriatal synaptic plasticity in transgenic mice overexpressing human CU/ZN superoxide dismutase (GLY93 $\hat{+}$ ALA) mutation. <i>Neuroscience</i> , 2003, 118, 399-408.	2.3	38
372	The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction?. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 172-177.	8.7	174
373	Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors. <i>Journal of Neuroscience</i> , 2003, 23, 3136-3144.	3.6	237
374	Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons. <i>NeuroReport</i> , 2002, 13, 1167-1170.	1.2	74
375	Group I metabotropic glutamate receptors activate burst firing in rat midbrain dopaminergic neurons. <i>Neuropharmacology</i> , 2002, 42, 289-296.	4.1	45
376	Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons. <i>Behavioural Brain Research</i> , 2002, 130, 149-169.	2.2	85
377	Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu,Zn superoxide dismutase. <i>Neuroscience Letters</i> , 2002, 325, 124-128.	2.1	10
378	Kainate $\hat{+}$ induced currents in rat cortical neurons in culture are modulated by riluzole. <i>Synapse</i> , 2002, 43, 244-251.	1.2	30

#	ARTICLE	IF	CITATIONS
379	Dopamine selectively reduces GABA B transmission onto dopaminergic neurones by an unconventional presynaptic action. <i>Journal of Physiology</i> , 2002, 540, 119-128.	2.9	17
380	New Insights Into mGluRs Function in the Substantia Nigra Pars Compacta. <i>Advances in Behavioral Biology</i> , 2002, , 223-232.	0.2	0
381	Group I mGluRs Coupled to G Proteins Are Regulated by Tyrosine Kinase in Dopamine Neurons of the Rat Midbrain. <i>Journal of Neurophysiology</i> , 2001, 85, 2490-2497.	1.8	39
382	Hypoglycemia Enhances Ionotropic But Reduces Metabotropic Glutamate Responses in Substantia Nigra Dopaminergic Neurons. <i>Journal of Neurophysiology</i> , 2001, 85, 1159-1166.	1.8	19
383	Glutamate receptor stimulation induces a persistent rhythmicity of the GABAergic inputs to rat midbrain dopaminergic neurons. <i>European Journal of Neuroscience</i> , 2001, 14, 777-784.	2.6	14
384	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. <i>European Journal of Neuroscience</i> , 2001, 14, 1492-1504.	2.6	140
385	Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. <i>Brain Research</i> , 2001, 919, 259-268.	2.2	20
386	Tranlycypromine, but not moclobemide, prolongs the inhibitory action of dopamine on midbrain dopaminergic neurons: An in vitro electrophysiological study. <i>Synapse</i> , 2000, 37, 216-221.	1.2	4
387	Effect of P2 purinoceptor antagonists on kainate-induced currents in rat cultured neurons. <i>Brain Research</i> , 2000, 882, 26-35.	2.2	21
388	The <i>weaver</i> Mutation Reverses the Function of Dopamine and GABA in Mouse Dopaminergic Neurons. <i>Journal of Neuroscience</i> , 2000, 20, 6013-6020.	3.6	19
389	Alpha1-adrenoceptor-mediated excitation of substantia nigra pars reticulata neurons. <i>Neuroscience</i> , 2000, 98, 599-604.	2.3	34
390	Muscarinic receptors depress GABAergic synaptic transmission in rat midbrain dopamine neurons. <i>Neuroscience</i> , 2000, 96, 299-307.	2.3	50
391	Pharmacological identification of the K ⁺ currents mediating the hypoglycemic hyperpolarization of rat midbrain dopaminergic neurones. <i>Neuropharmacology</i> , 2000, 39, 1021-1028.	4.1	28
392	Group I Metabotropic Glutamate Receptors Mediate an Inward Current in Rat Substantia Nigra Dopamine Neurons That Is Independent From Calcium Mobilization. <i>Journal of Neurophysiology</i> , 1999, 82, 1974-1981.	1.8	60
393	Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons. <i>European Journal of Neuroscience</i> , 1999, 11, 593-598.	2.6	20
394	Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: an in vitro electrophysiological evidence from rat mesencephalic dopamine neurons. <i>Journal of Neural Transmission</i> , 1999, 106, 1135-1140.	2.8	5
395	Neuroprotective effects of riluzole: An electrophysiological and histological analysis in an in vitro model of ischemia. <i>Synapse</i> , 1999, 32, 147-152.	1.2	25
396	Presynaptic muscarinic (M3) receptors reduce excitatory transmission in dopamine neurons of the rat mesencephalon. <i>Neuroscience</i> , 1999, 91, 557-565.	2.3	41

#	ARTICLE	IF	CITATIONS
397	Neuroprotective effects of riluzole: An electrophysiological and histological analysis in an in vitro model of ischemia. <i>Synapse</i> , 1999, 32, 147-152.	1.2	1
398	Modification of levodopa responses by deprenyl (selegiline): An electrophysiological and behavioral study in the rat relevant to Parkinson's disease. <i>Annals of Neurology</i> , 1998, 43, 613-617.	5.3	8
399	An electrophysiological analysis of the protective effects of felbamate, lamotrigine, and lidocaine on the functional recovery from in vitro ischemia in rat neocortical slices. <i>Synapse</i> , 1998, 30, 371-379.	1.2	19
400	Hyperpolarization induces a rise in intracellular sodium concentration in dopamine cells of the substantia nigra pars compacta. <i>European Journal of Neuroscience</i> , 1998, 10, 1926-1929.	2.6	26
401	Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. <i>Neuroscience</i> , 1998, 85, 931-938.	2.3	110
402	Voltage-activated sodium currents in a cell line expressing a Cu,Zn superoxide dismutase typical of familial ALS. <i>NeuroReport</i> , 1998, 9, 3515-3518.	1.2	20
403	L-Type Calcium Channels Mediate a Slow Excitatory Synaptic Transmission in Rat Midbrain Dopaminergic Neurons. <i>Journal of Neuroscience</i> , 1998, 18, 6693-6703.	3.6	75
404	Whole Cell Patch-Clamp Recordings of Rat Midbrain Dopaminergic Neurons Isolate a Sulphonylurea- and ATP-Sensitive Component of Potassium Currents Activated by Hypoxia. <i>Journal of Neurophysiology</i> , 1998, 79, 1239-1245.	1.8	48
405	Intracellular Sodium and Calcium Homeostasis During Hypoxia in Dopamine Neurons of Rat Substantia Nigra Pars Compacta. <i>Journal of Neurophysiology</i> , 1998, 80, 2237-2243.	1.8	34
406	Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 232-235.	8.7	13
407	Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 232-235.	8.7	14
408	Correspondence. <i>Neuroscience</i> , 1997, 79, 323-327.	2.3	190
409	Epileptiform discharge induced by 4-aminopyridine in magnesium-free medium in neocortical neurons: physiological and pharmacological characterization. <i>Neuroscience</i> , 1997, 81, 189-197.	2.3	40
410	Monoamine Oxidase Inhibition Causes a Long-Term Prolongation of the Dopamine-Induced Responses in Rat Midbrain Dopaminergic Cells. <i>Journal of Neuroscience</i> , 1997, 17, 2267-2272.	3.6	34
411	Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors. <i>Journal of Neuroscience</i> , 1997, 17, 4536-4544.	3.6	279
412	Glutamate Metabotropic Receptor Agonists Depress Excitatory and Inhibitory Transmission on Rat Mesencephalic Principal Neurons. <i>European Journal of Neuroscience</i> , 1997, 9, 2359-2369.	2.6	56
413	Effects of riluzole on rat cortical neurones: an in vitro electrophysiological study. <i>British Journal of Pharmacology</i> , 1997, 120, 225-230.	5.4	44
414	Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study. <i>British Journal of Pharmacology</i> , 1996, 117, 528-532.	5.4	15

#	ARTICLE	IF	CITATIONS
415	N-Methyl-d-aspartate receptors mediate a slow excitatory postsynaptic potential in the rat midbrain dopaminergic neurons. <i>Neuroscience</i> , 1996, 74, 785-792.	2.3	20
416	The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. <i>Trends in Neurosciences</i> , 1996, 19, 19-24.	8.6	420
417	The modulation of calcium currents by the activation of mGluRs. <i>Molecular Neurobiology</i> , 1996, 13, 81-95.	4.0	54
418	Characterization of a Barium-sensitive Outward Current following Glutamate Application on Rat Midbrain Dopaminergic Cells. <i>European Journal of Neuroscience</i> , 1996, 8, 1780-1786.	2.6	8
419	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. I. Modulation of Corticostriatal Synaptic Transmission. <i>Epilepsia</i> , 1995, 36, 990-996.	5.1	51
420	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High-Voltage-Activated Calcium Currents. <i>Epilepsia</i> , 1995, 36, 997-1002.	5.1	101
421	Hypoxia-Induced Electrical Changes in Striatal Neurons. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1995, 15, 1141-1145.	4.3	17
422	Properties of the Hyperpolarization-activated Cation Current I _h in Rat Midbrain Dopaminergic Neurons. <i>European Journal of Neuroscience</i> , 1995, 7, 462-469.	2.6	190
423	Actions of Glycine on Non-dopaminergic Neurons of the Rat Substantia Nigra. <i>European Journal of Neuroscience</i> , 1995, 7, 2351-2354.	2.6	5
424	Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na ⁺ /K ⁺ ATPase. <i>European Journal of Neuroscience</i> , 1995, 7, 1674-1683.	2.6	78
425	Transmitter Release Associated with Long-term Synaptic Depression in Rat Corticostriatal Slices. <i>European Journal of Neuroscience</i> , 1995, 7, 1889-1894.	2.6	37
426	Electrophysiology of dopamine D-1 receptors in the basal ganglia: Old facts and new perspectives. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1995, 19, 779-793.	4.8	5
427	Electrophysiological actions of felbamate on rat striatal neurones. <i>British Journal of Pharmacology</i> , 1995, 116, 2053-2061.	5.4	45
428	Long-Term Changes of Corticostriatal Synaptic Transmission: Possible Implication for Motor Memory. , 1995, , 89-103.		3
429	Effects of anoxia on rat midbrain dopamine neurons. <i>Journal of Neurophysiology</i> , 1994, 71, 1165-1173.	1.8	48
430	Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons. <i>Journal of Neuroscience</i> , 1994, 14, 6734-6743.	3.6	95
431	Responses of rat mesencephalic dopaminergic neurons to a prolonged period of oxygen deprivation. <i>Neuroscience</i> , 1994, 63, 757-764.	2.3	20
432	Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. <i>British Journal of Pharmacology</i> , 1994, 113, 831-838.	5.4	133

#	ARTICLE	IF	CITATIONS
433	Basic Electrophysiology and Possible New Therapeutic Approaches to Movement Disorders. <i>Advances in Behavioral Biology</i> , 1994, , 229-237.	0.2	1
434	Heterogeneity of Metabotropic Glutamate Receptors in the Striatum: Electrophysiological Evidence. <i>European Journal of Neuroscience</i> , 1993, 5, 1370-1377.	2.6	66
435	Activation of metabotropic glutamate receptors induces an inward current in rat dopamine mesencephalic neurons. <i>Neuroscience</i> , 1993, 56, 399-407.	2.3	69
436	Lithium Treatment Blocks Long-Term Synaptic Depression in the Striatum. <i>Neuron</i> , 1993, 10, 955-962.	8.1	43
437	Neurotensin induces an inward current in rat mesencephalic dopaminergic neurons. <i>Neuroscience Letters</i> , 1993, 153, 192-196.	2.1	39
438	Chapter 19 Chemical modulation of synaptic transmission in the striatum. <i>Progress in Brain Research</i> , 1993, 99, 299-308.	1.4	18
439	5-hydroxytryptamine _{1B} receptors block the GABAB synaptic potential in rat dopamine neurons. <i>Journal of Neuroscience</i> , 1992, 12, 2000-2006.	3.6	240
440	Actions of Levodopa on rat substantia nigra zona compacta neurons. <i>Neurochemistry International</i> , 1992, 20, 207-209.	3.8	8
441	The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. <i>Life Sciences</i> , 1992, 51, 711-718.	4.3	74
442	Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. <i>Neuroscience Letters</i> , 1992, 142, 95-99.	2.1	186
443	A-current in rat globus pallidus: A whole-cell voltage clamp study on acutely dissociated neurons. <i>Neuroscience Letters</i> , 1992, 144, 4-8.	2.1	14
444	Activation of quisqualate metabotropic receptors reduces glutamate and GABA-mediated synaptic potentials in the rat striatum. <i>Neuroscience Letters</i> , 1992, 139, 41-44.	2.1	92
445	A voltage-clamp analysis of NMDA-induced responses on dopaminergic neurons of the rat substantia nigra zona compacta and ventral tegmental area. <i>Brain Research</i> , 1992, 593, 51-56.	2.2	34
446	Long-term Potentiation in the Striatum is Unmasked by Removing the Voltage-dependent Magnesium Block of NMDA Receptor Channels. <i>European Journal of Neuroscience</i> , 1992, 4, 929-935.	2.6	380
447	Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. <i>Annals of Neurology</i> , 1992, 31, 366-373.	5.3	78
448	Electrophysiological effects of amineptine on neurones of the rat substantia nigra pars compacta: evidence for an inhibition of the dopamine uptake system. <i>British Journal of Pharmacology</i> , 1991, 104, 700-704.	5.4	12
449	Nomifensine but not amantadine increases dopamine-induced responses on rat substantia nigra zona compacta neurons. <i>Neuroscience Letters</i> , 1991, 131, 145-148.	2.1	13
450	Dopamine uptake inhibition potentiates the effects of l-DOPA on rat substantia nigra zona compacta neurons. <i>Neuroscience Letters</i> , 1991, 126, 79-82.	2.1	11

#	ARTICLE	IF	CITATIONS
451	Involvement of GABA systems in feedback regulation of glutamate-and GABA-mediated synaptic potentials in rat neostriatum.. <i>Journal of Physiology</i> , 1991, 440, 581-599.	2.9	119
452	GABA depolarizes neurons in the rat striatum: An in vivo study. <i>Synapse</i> , 1991, 8, 38-40.	1.2	33
453	Effects of glycine on neurons in the rat substantia nigra zona compacta: In vitro electrophysiological study. <i>Synapse</i> , 1990, 5, 190-200.	1.2	18
454	Synaptic and intrinsic control of membrane excitability of neostriatal neurons. I. An in vivo analysis. <i>Journal of Neurophysiology</i> , 1990, 63, 651-662.	1.8	122
455	Kainic acid on neostriatal neurons intracellularly recorded in vitro: electrophysiological evidence for differential neuronal sensitivity. <i>Journal of Neuroscience</i> , 1990, 10, 3960-3969.	3.6	28
456	Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum. <i>Neuroscience Letters</i> , 1990, 118, 99-102.	2.1	50
457	Actions of cocaine on rat dopaminergic neurones <i>in vitro</i>. <i>British Journal of Pharmacology</i> , 1990, 99, 731-735.	5.4	116
458	Responses of rat substantia nigra compacta neurones to Lâ€DOPA. <i>British Journal of Pharmacology</i> , 1990, 100, 257-260.	5.4	48
459	Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids. <i>Journal of Neuroscience</i> , 1989, 9, 1233-1241.	3.6	394
460	Met- and leu-enkephalins inhibit rat cortical neurons intracellularly recorded in vivo while morphine excites them: evidence for naloxone-sensitive and naloxone-insensitive effects. <i>Experimental Brain Research</i> , 1989, 77, 302-308.	1.5	13
461	Selective depression of synaptic transmission by tetanus toxin: A comparative study on hippocampal and neostriatal slices. <i>Neuroscience</i> , 1989, 30, 663-670.	2.3	36
462	The mechanism of amphetamineâ€induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording <i>in vitro</i>. <i>British Journal of Pharmacology</i> , 1989, 98, 127-134.	5.4	45
463	Physiology and pharmacology of dopamine D ₂ â€receptors. <i>Neurology</i> , 1989, 39, 1106-1106.	1.1	14
464	Potassium ions play a role in the glycine-induced inhibition of rat substantia nigra zona compacta neurones. <i>Brain Research</i> , 1988, 462, 199-203.	2.2	16
465	Depletion of catecholamines reveals inhibitory effects of bromocryptine and lysuride on neostriatal neurones recorded intracellularly in vitro. <i>Neuropharmacology</i> , 1988, 27, 579-587.	4.1	19
466	Endogenous dopamine and dopaminergic agonists modulate synaptic excitation in neostriatum: Intracellular studies from naive and catecholamine-depleted rats. <i>Neuroscience</i> , 1988, 27, 145-157.	2.3	62
467	On the potassium conductance increase activated by GABAB and dopamine D2 receptors in rat substantia nigra neurones.. <i>Journal of Physiology</i> , 1988, 401, 437-453.	2.9	309
468	Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta.. <i>Journal of Physiology</i> , 1987, 392, 397-416.	2.9	545

#	ARTICLE	IF	CITATIONS
469	Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: Evidence for D1 receptor involvement. <i>Neuroscience</i> , 1987, 20, 757-771.	2.3	261
470	Action of morphine on rat cortical neurons intracellularly recorded in vivo: Evidence for an excitatory postsynaptic effect which is naloxone insensitive. <i>Neuroscience</i> , 1986, 18, 31-41.	2.3	5
471	Electrical stimulation of mesencephalic cell groups (A9-A10) produces monosynaptic excitatory potentials in rat frontal cortex. <i>Brain Research</i> , 1985, 338, 192-195.	2.2	33
472	Dopamine decreases cell excitability in rat striatal neurons by pre- and postsynaptic mechanisms. <i>Brain Research</i> , 1985, 358, 110-121.	2.2	92
473	Short-latency scalp somatosensory evoked potentials and central spine to scalp propagation characteristics during peroneal and median nerve stimulation in multiple sclerosis. <i>Electroencephalography and Clinical Neurophysiology</i> , 1985, 60, 197-206.	0.3	22
474	Dopamine modulates CA1 hippocampal neurons by elevating the threshold for spike generation: An in vitro study. <i>Neuroscience</i> , 1984, 13, 1105-1116.	2.3	72
475	Responses of intracellularly recorded cortical neurons to the iontophoretic application of dopamine. <i>Brain Research</i> , 1982, 245, 267-274.	2.2	138
476	Multiple opiate receptors on neurons of the mammalian central nervous system. In vivo and in vitro studies. <i>Life Sciences</i> , 1982, 31, 2343-2346.	4.3	22
477	The action of glycine on rat epileptic foci. <i>Neuroscience Letters</i> , 1981, 21, 93-97.	2.1	13